LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

February 16, 2023

https://www.globenewswire.com/news-release/2023/02/16/2609539/0/en/LAVA-Therapeutics-Announces-Initial-Data-from-the-Ongoing-Phase-1-2a-Clinical-Trial-of-LAVA-1207-in-Therapy-Refractory-mCRPC-at-the-2023-ASCO-GU-Symposium.html

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 16, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced initial clinical data from its ongoing Phase 1/2a study of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer (mCRPC). The data are presented in a poster presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) taking place in San Francisco from February 16-18, 2023.

Read more at globenewswire.com

Related news for (LVTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.